Viridian Therapeutics ( (VRDN) ) has shared an announcement.
On March 3, 2025, Viridian Therapeutics entered into a new Open Market Sale Agreement with Jefferies LLC, allowing the company to offer and sell up to $300 million in common stock to support clinical development and commercialization efforts. This new agreement replaces a prior sale agreement from September 2022, which was terminated after selling $115.2 million in stock, with no costs associated with its early termination.
More about Viridian Therapeutics
Viridian Therapeutics, Inc. operates in the biotechnology industry, focusing on the clinical development and potential commercialization of its product candidates, including veligrotug. The company aims to advance its pipeline and prepare for market entry pending regulatory approvals.
YTD Price Performance: -21.41%
Average Trading Volume: 1,339,591
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $1.23B
See more data about VRDN stock on TipRanks’ Stock Analysis page.